Product InnovationGene editing is expected to accelerate genetic yield gains and incorporate crop protection traits, leading to branded and licensee market share gains.
Revenue GrowthCorteva expects $1B incremental sales growth from out-licensing, new CP products, and Biologicals, showing potential for substantial revenue increase.
Shareholder ReturnsThe new $3 billion share buyback program indicates significant return of capital to shareholders.